Here are three things to know.
1. Ixifi is a biosimilar version of Johnson & Johnson’s immunosuppressive drug Remicade.
2. The drug is intended to treat rheumatoid arthritis, Crohn’s disease and plaque psoriasis, among other illnesses.
3. Both Ixifi and Remicade contain a boxed warning over an increased risk of serious infections and cancer.
More articles on supply chain:
Eli Lilly forecasts $23B in revenue for 2018
Investor group pushes big pharma to report links between pricing and executive compensation
FDA to add alternative approval pathway for medical devices: 4 things to know
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
